Anavex received agreement from the committee for medicinal products for human use (chmp) for the submission of a marketing authorisation application of oral blarcamesine for alzheimer's disease

New york, dec. 19, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, announced today that the committee for medicinal products for human use (chmp) within the european medicines agency (ema) agreed that oral blarcamesine for alzheimer's disease is eligible for submission of an application for a union marketing authorisation in the eu under the european medicines agency's centralised procedure.
AVXL Ratings Summary
AVXL Quant Ranking